CytomX Therapeutics (NASDAQ:CTMX) Upgraded to “Neutral” at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from an underweight rating to a neutral rating in a research note published on Monday morning, MarketBeat.com reports.

CytomX Therapeutics Price Performance

Shares of CTMX opened at $1.67 on Monday. The stock’s fifty day simple moving average is $2.04 and its 200-day simple moving average is $1.63. The firm has a market capitalization of $113.11 million, a PE ratio of -83.46 and a beta of 1.01. CytomX Therapeutics has a 12-month low of $1.04 and a 12-month high of $2.86.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, March 11th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.01). The business had revenue of $26.61 million for the quarter, compared to the consensus estimate of $23.36 million. Analysts anticipate that CytomX Therapeutics will post -0.21 EPS for the current year.

Insider Buying and Selling at CytomX Therapeutics

In other news, CEO Sean A. Mccarthy sold 20,223 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total value of $42,266.07. Following the transaction, the chief executive officer now owns 524,481 shares of the company’s stock, valued at approximately $1,096,165.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 35,024 shares of company stock valued at $73,200. 7.00% of the stock is currently owned by insiders.

Institutional Trading of CytomX Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AlphaMark Advisors LLC grew its holdings in CytomX Therapeutics by 119.8% during the fourth quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 12,635 shares during the period. Congress Park Capital LLC boosted its position in shares of CytomX Therapeutics by 112.8% during the fourth quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 126,850 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of CytomX Therapeutics by 737.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 234,970 shares during the period. 67.77% of the stock is owned by institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.